Background: Parkinson's disease (PD) is a common neurodegenerative disorder. Epidemiological studies on the incidence of PD are important to better understand the risk factors for PD and determine the condition's natural history. Objective: This systematic review and meta-analysis examine the incidence of PD and its variation by age and gender. Methods: We searched MEDLINE and EMBASE for epidemiologic studies of PD from 2001 to 2014, as a previously published systematic review included studies published until 2001. Data were analyzed separately for age group and gender, and meta-regression was used to determine whether a significant difference was present between groups. Results: Twenty-seven studies were included in the analysis. Meta-analysis of international studies showed rising incidence with age in both men and women. Significant heterogeneity was observed in the 80+ group, which may be explained by methodological differences between studies. While males had a higher incidence of PD in all age groups, this difference was only statistically significant for those in the age range 60-69 and 70-79 (p < 0.05). Conclusion: PD incidence generally increases with age, although it may stabilize in those who are 80+.

Keywords:
Incidence studies, Parkinson’s disease/parkinsonism, Risk factors in epidemiology
1.
Twelves D, Perkins KS, Counsell C: Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31.
2.
Pringsheim T, Jette N, Frolkis A, Steeves TD: The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29:1583-1590.
3.
Boyle MH: Guidelines for evaluating prevalence studies. Evid Based Men Health 1998;1:37-39.
4.
Loney PL, Chambers LW, Bennett KJ, Roberts JG, Stratford PW: Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Can 1998;19:170-176.
5.
Alves G, Muller B, Herlofson K, et al: Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009;80:851-857.
6.
Bauso DJ: Incidence and prevalence of Parkinson's disease in Buenos Aires City, Argentina. Parkinsons Dis 2014;24:50-52.
7.
Benito-Leon J, Bermejo-Pareja F, Morales-Gonzalez JM, et al: Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004;62:734-741.
8.
Caslake R, Taylor K, Scott N, et al: Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in northeast Scotland: the PINE study. Parkinsonism Relat Disord 2013;19:515-521.
9.
Chen RC, Chang SF, Su CL, et al: Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001;57:1679-1686.
10.
de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM: Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam study. Neurology 2004;63:1240-1244.
11.
Driver JA, Logroscino G, Gaziano JM, Kurth T: Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009;72:432-438.
12.
Duncan GW, Khoo TK, Coleman SY, et al: The incidence of Parkinson's disease in the north-east of England. Age Ageing 2014;43:257-263.
13.
Allyson Jones C, Wayne Martin WR, Wieler M, King-Jesso P, Voaklander DC: Incidence and mortality of Parkinson's disease in older Canadians. Parkinsonism Relat Disord 2012;18:327-331.
14.
Linder J, Stenlund H, Forsgren L: Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Mov Disord 2010;25:341-348.
15.
Morioka S, Sakata K, Yoshida S, et al: Incidence of Parkinson disease in Wakayama, Japan. J Epidemiol 2002;12:403-407.
16.
Tan LC, Venketasubramanian N, Jamora RD, Heng D: Incidence of Parkinson's disease in Singapore. Parkinsonism Relat Disord 2007;13:40-43.
17.
Van Den Eeden SK, Tanner CM, Bernstein AL, et al: Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
18.
Winter Y, Bezdolnyy Y, Katunina E, et al: Incidence of Parkinson's disease and atypical parkinsonism: Russian population-based study. Mov Disord 2010;25:349-356.
19.
Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV: Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 2006;21:1221-1225.
20.
Horsfall L, Petersen I, Walters K, Schrag A: Time trends in incidence of Parkinson's disease diagnosis in UK primary care. J Neurol 2013;260:1351-1357.
21.
Hristova D, Zachariev Z, Mateva N, Grozdev I: Incidence of Parkinson's disease in Bulgaria. Neuroepidemiology 2010;34:76-82.
22.
Kyrozis A, Ghika A, Stathopoulos P, Vassilopoulos D, Trichopoulos D, Trichopoulou A: Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece. Eur J Epidemiol 2013;28:67-77.
23.
Leentjens AF, Van den Akker M, Metsemakers JF, Troost J: The incidence of Parkinson's disease in the Netherlands: results from a longitudinal general practice-based registration. Neuroepidemiology 2003;22:311-312.
24.
Perez F, Helmer C, Dartigues JF, Auriacombe S, Tison F: A 15-year population-based cohort study of the incidence of Parkinson's disease and dementia with Lewy bodies in an elderly French cohort. J Neurol Neurosurg Psychiatry 2010;81:742-746.
25.
Taba P, Asser T: Incidence of Parkinson's disease in estonia. Neuroepidemiology 2003;22:41-45.
26.
van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A: Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. Pharmacoepidemiol Drug Saf 2001;10:549-554.
27.
Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, Grandjean P: Prevalence and incidence of Parkinson's disease in the Faroe Islands. Acta Neurol Scand 2008;118:126-131.
28.
Chillag-Talmor O, Giladi N, Linn S, et al: Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large Israeli population. J Parkinsons Dis 2011;1:35-47.
29.
Das SK, Misra AK, Ray BK, et al: Epidemiology of Parkinson disease in the city of Kolkata, India: a community-based study. Neurology 2010;75:1362-1369.
30.
Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA: Geographic and ethnic variation in Parkinson disease: a population-based study of us Medicare beneficiaries. Neuroepidemiology 2010;34:143-151.
31.
Mehta P, Kifley A, Wang JJ, Rochtchina E, Mitchell P, Sue CM: Population prevalence and incidence of Parkinson's disease in an Australian community. Intern Med J 2007;37:812-814.
32.
de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM: A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997;48:1277-1281.
33.
Chiò A, Magnani C, Schiffer D: Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998;13:400-405.
34.
St Germaine-Smith C, Metcalfe A, Pringsheim T, et al: Recommendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology 2012;79:1049-1055.
35.
Pringsheim T, Jette N, Frolkis A, Lam D, Steeves TD: The prevalence of Parkinson disease: a systematic review and meta-analysis. Neurology 2013;80:1 meeting abstracts.
36.
Haaxma C, Bloem BR, Borm GF, et al: Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:819-824.
37.
Xu J, Gong DD, Man CF, Fan Y: Parkinson's disease and risk of mortality: meta-analysis and systematic review. Acta Neurol Scand 2014;129:71-79.
38.
Diem-Zangerl A, Seppi K, Wenning GK, et al: Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009;24:819-825.
39.
Bennett D, Brayne C, Feigin VL, et al: Development of the standards of reporting of neurological disorders (STROND) checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. Eur J Epidemiol 2015;30:569-576.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.